Podcasts

E-Books

Videos

Articles

Business & Practice

Tony Hagen is senior managing editor for The Center for Biosimilars

Shanghai Henlius Biotech has been given the green light to market its trastuzumab biosimilar (Zercepac, HLX02) in the European Union. Accord Healthcare will handle the distribution.

Henlius Biotech Gets EC Marketing Approval for Zercepac

If you can’t beat biosimilars, join them, is the mantra; but at Amgen there’s still gold in originator products, according to its latest earnings report.

Amgen Reports Double-Edged Biosimilars Results

Biologics are not cheap, and if you can get biosimilars into the hands of patients, you’ve got something going. A strategist describes the step-by-step process that made this possible at Kaiser Permanente.

How Kaiser Permanente Got Biosimilars Into Play

Although more advanced than in the United States, biosimilars markets in Europe may discourage competition over the long term, said officials from Medicines for Europe.

Interview: EU Biosimilars Markets Lack Competition

While Amgen fends off etanercept biosimilar competition in the United States, Pfizer said it is facing a mounting battle against biosimilar competition in European and other markets.

Pfizer Reports Continued Weakness for Enbrel in Europe

Kris Soyoung Lee is the vice president of the Supply Chain Management team at Samsung Bioepis of Incheon, Republic of Korea. She has more than 20 years of experience in supply chain management across various industries, including chemical, pharmaceutical, and biopharmaceutical.

How Samsung Bioepis Has Restructured Its Supply Chain Amid the Pandemic

Skylar Jeremias is the Managing Editor for The Center for Biosimilars and The American Journal of Managed Care (AJMC).

Cadila Pharmaceuticals has launched a bevacizumab biosimilar referencing Avastin in India. Bevacizumab is used for the treatment of colorectal, breast, and lung cancers, among others.

Cadila Pharmaceuticals Launches Avastin Biosimilar in India

For Biocon, overall revenues were up during the fiscal quarter that just ended, driven by strong revenues in its biosimilars and generics operations.

Biocon Reports Strong Quarter for Its Biosimilars Unit

The company saw a 7% decline in biosimilar revenues in the second quarter of 2020 compared with the same quarter in 2019.
 

Biogen Biosimilar Revenues Dip Amid COVID-19 Pandemic

China-based Bio-Thera Solutions is breaking into the growing Russian biosimilar market by licensing the marketing rights for its unapproved golimumab biosimilar to Russian biopharmaceutical company Pharmapark.
 

Business